Trigg M E, Makuch R, Glaubiger D
Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):699-702. doi: 10.1016/0360-3016(85)90300-1.
Records of 154 patients with Ewing's sarcoma treated at the National Cancer Institute were reviewed to assess the incidence and risk of developing isolated central nervous system (CNS) Ewing's sarcoma. Sixty-two of the 154 patients had received CNS irradiation and intrathecal (i.t.) methotrexate as part of their initial therapy to prevent the occurrence of isolated CNS Ewing's sarcoma. The risk of developing isolated CNS Ewing's sarcoma was greatest within the first two years after diagnosis and was approximately 10%. The overall risk of CNS recurrence in the group of patients receiving CNS treatment was similar to the group receiving no therapy directed to the CNS. The occurrence of isolated CNS involvement was not prevented by the use of CNS irradiation and i.t. methotrexate. Because of a lack of efficacy to the CNS irradiation regimen, current treatment regimens do not include therapy directed to the CNS.
回顾了在国立癌症研究所接受治疗的154例尤因肉瘤患者的记录，以评估孤立性中枢神经系统（CNS）尤因肉瘤的发生率和发病风险。154例患者中有62例在初始治疗时接受了中枢神经系统照射和鞘内注射甲氨蝶呤，以预防孤立性中枢神经系统尤因肉瘤的发生。孤立性中枢神经系统尤因肉瘤的发病风险在诊断后的头两年内最高，约为10%。接受中枢神经系统治疗的患者组中中枢神经系统复发的总体风险与未接受针对中枢神经系统治疗的患者组相似。使用中枢神经系统照射和鞘内注射甲氨蝶呤并不能预防孤立性中枢神经系统受累的发生。由于中枢神经系统照射方案缺乏疗效，目前的治疗方案不包括针对中枢神经系统的治疗。
